APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rare Disease Drug Market Analysis and Forecast 2026-2032

20 December 2025211 pages

Choose your research edition.

Industry ResearchRare Disease Drug Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Rare Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Drug Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Drug Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Rare Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Rare Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rare Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rare Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rare Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Rare Disease Drug include Alexion Pharmaceuticals, Inc., Amgen, Inc., Atara Biotherapeutics, Bayer AG, Biogen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited and Deciphera, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rare Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rare Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Rare Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rare Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rare Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Rare Disease Drug sales, projected growth trends, production technology, application and end-user industry.

Rare Disease Drug Segment by Company

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

Atara Biotherapeutics

Bayer AG

Biogen, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Daiichi Sankyo Company Limited

Deciphera

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Novo Nordisk A/S

ProQR

AstraZeneca

GlaxoSmithKline

Pfizer, Inc.

Eli Lilly and Company

Merck & Co., Inc.

Novartis AG

Johnson & Johnson

Sanofi S.A.

Takeda

Rare Disease Drug Segment by Type

Below 0.1‰

Above 1‰

0.65‰～1‰

Rare Disease Drug Segment by Application

Speciality Pharmacies

Hospital Pharmacies

Retail pharmacies

Others

Rare Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Rare Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Rare Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rare Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Below 0.1‰ Major Manufacturers Table 3. Above 1‰ Major Manufacturers Table 4. 0.65‰～1‰ Major Manufacturers Table 5. Global Rare Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Speciality Pharmacies Major Manufacturers Table 7. Hospital Pharmacies Major Manufacturers Table 8. Retail pharmacies Major Manufacturers Table 9. Others Major Manufacturers Table 10. Rare Disease Drug Industry Trends Table 11. Rare Disease Drug Industry Drivers Table 12. Rare Disease Drug Industry Opportunities and Challenges Table 13. Rare Disease Drug Industry Restraints Table 14. Global Rare Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Rare Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Rare Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Rare Disease Drug Revenue Market Share by Region (2021-2026) Table 18. Global Rare Disease Drug Revenue Market Share by Region (2027-2032) Table 19. Global Rare Disease Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Rare Disease Drug Sales by Region (2021-2026) & (K Units) Table 21. Global Rare Disease Drug Sales by Region (2027-2032) & (K Units) Table 22. Global Rare Disease Drug Sales Market Share by Region (2021-2026) Table 23. Global Rare Disease Drug Sales Market Share by Region (2027-2032) Table 24. Global Rare Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Rare Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Rare Disease Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Rare Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Rare Disease Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Rare Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Rare Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Rare Disease Drug Manufacturers, Product Type & Application Table 32. Global Rare Disease Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Rare Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Rare Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Rare Disease Drug Revenue Market Share by Type (2021-2026) Table 39. Global Rare Disease Drug Revenue Market Share by Type (2027-2032) Table 40. Global Rare Disease Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 42. Global Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 43. Global Rare Disease Drug Sales Market Share by Type (2021-2026) Table 44. Global Rare Disease Drug Sales Market Share by Type (2027-2032) Table 45. Global Rare Disease Drug Price by Type (2021-2026) & (US$/Unit) Table 46. Global Rare Disease Drug Price by Type (2027-2032) & (US$/Unit) Table 47. Global Rare Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Rare Disease Drug Revenue Market Share by Application (2021-2026) Table 51. Global Rare Disease Drug Revenue Market Share by Application (2027-2032) Table 52. Global Rare Disease Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 54. Global Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 55. Global Rare Disease Drug Sales Market Share by Application (2021-2026) Table 56. Global Rare Disease Drug Sales Market Share by Application (2027-2032) Table 57. Global Rare Disease Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Rare Disease Drug Price by Application (2027-2032) & (US$/Unit) Table 59. Alexion Pharmaceuticals, Inc. Company Information Table 60. Alexion Pharmaceuticals, Inc. Business Overview Table 61. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio Table 63. Alexion Pharmaceuticals, Inc. Recent Development Table 64. Amgen, Inc. Company Information Table 65. Amgen, Inc. Business Overview Table 66. Amgen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Amgen, Inc. Rare Disease Drug Product Portfolio Table 68. Amgen, Inc. Recent Development Table 69. Atara Biotherapeutics Company Information Table 70. Atara Biotherapeutics Business Overview Table 71. Atara Biotherapeutics Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Atara Biotherapeutics Rare Disease Drug Product Portfolio Table 73. Atara Biotherapeutics Recent Development Table 74. Bayer AG Company Information Table 75. Bayer AG Business Overview Table 76. Bayer AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bayer AG Rare Disease Drug Product Portfolio Table 78. Bayer AG Recent Development Table 79. Biogen, Inc. Company Information Table 80. Biogen, Inc. Business Overview Table 81. Biogen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Biogen, Inc. Rare Disease Drug Product Portfolio Table 83. Biogen, Inc. Recent Development Table 84. Bristol-Myers Squibb Company Company Information Table 85. Bristol-Myers Squibb Company Business Overview Table 86. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio Table 88. Bristol-Myers Squibb Company Recent Development Table 89. Celgene Corporation Company Information Table 90. Celgene Corporation Business Overview Table 91. Celgene Corporation Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Celgene Corporation Rare Disease Drug Product Portfolio Table 93. Celgene Corporation Recent Development Table 94. Daiichi Sankyo Company Limited Company Information Table 95. Daiichi Sankyo Company Limited Business Overview Table 96. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio Table 98. Daiichi Sankyo Company Limited Recent Development Table 99. Deciphera Company Information Table 100. Deciphera Business Overview Table 101. Deciphera Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Deciphera Rare Disease Drug Product Portfolio Table 103. Deciphera Recent Development Table 104. Eisai Co., Ltd. Company Information Table 105. Eisai Co., Ltd. Business Overview Table 106. Eisai Co., Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eisai Co., Ltd. Rare Disease Drug Product Portfolio Table 108. Eisai Co., Ltd. Recent Development Table 109. F. Hoffmann-La Roche Ltd. Company Information Table 110. F. Hoffmann-La Roche Ltd. Business Overview Table 111. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio Table 113. F. Hoffmann-La Roche Ltd. Recent Development Table 114. Novo Nordisk A/S Company Information Table 115. Novo Nordisk A/S Business Overview Table 116. Novo Nordisk A/S Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novo Nordisk A/S Rare Disease Drug Product Portfolio Table 118. Novo Nordisk A/S Recent Development Table 119. ProQR Company Information Table 120. ProQR Business Overview Table 121. ProQR Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. ProQR Rare Disease Drug Product Portfolio Table 123. ProQR Recent Development Table 124. AstraZeneca Company Information Table 125. AstraZeneca Business Overview Table 126. AstraZeneca Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. AstraZeneca Rare Disease Drug Product Portfolio Table 128. AstraZeneca Recent Development Table 129. GlaxoSmithKline Company Information Table 130. GlaxoSmithKline Business Overview Table 131. GlaxoSmithKline Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. GlaxoSmithKline Rare Disease Drug Product Portfolio Table 133. GlaxoSmithKline Recent Development Table 134. Pfizer, Inc. Company Information Table 135. Pfizer, Inc. Business Overview Table 136. Pfizer, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Pfizer, Inc. Rare Disease Drug Product Portfolio Table 138. Pfizer, Inc. Recent Development Table 139. Eli Lilly and Company Company Information Table 140. Eli Lilly and Company Business Overview Table 141. Eli Lilly and Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Eli Lilly and Company Rare Disease Drug Product Portfolio Table 143. Eli Lilly and Company Recent Development Table 144. Merck & Co., Inc. Company Information Table 145. Merck & Co., Inc. Business Overview Table 146. Merck & Co., Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Merck & Co., Inc. Rare Disease Drug Product Portfolio Table 148. Merck & Co., Inc. Recent Development Table 149. Novartis AG Company Information Table 150. Novartis AG Business Overview Table 151. Novartis AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Novartis AG Rare Disease Drug Product Portfolio Table 153. Novartis AG Recent Development Table 154. Johnson & Johnson Company Information Table 155. Johnson & Johnson Business Overview Table 156. Johnson & Johnson Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Johnson & Johnson Rare Disease Drug Product Portfolio Table 158. Johnson & Johnson Recent Development Table 159. Sanofi S.A. Company Information Table 160. Sanofi S.A. Business Overview Table 161. Sanofi S.A. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Sanofi S.A. Rare Disease Drug Product Portfolio Table 163. Sanofi S.A. Recent Development Table 164. Takeda Company Information Table 165. Takeda Business Overview Table 166. Takeda Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Takeda Rare Disease Drug Product Portfolio Table 168. Takeda Recent Development Table 169. North America Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 170. North America Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 171. North America Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 172. North America Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 173. North America Rare Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 174. North America Rare Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 175. North America Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 176. North America Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 177. North America Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 178. North America Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 179. North America Rare Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 180. North America Rare Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 181. North America Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 182. North America Rare Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 183. North America Rare Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 184. North America Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 185. North America Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 186. North America Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 187. North America Rare Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 188. North America Rare Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 189. United States Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 190. Canada Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 191. Europe Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 192. Europe Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 193. Europe Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 194. Europe Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 195. Europe Rare Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 196. Europe Rare Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 197. Europe Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 198. Europe Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 199. Europe Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 200. Europe Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 201. Europe Rare Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 202. Europe Rare Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 203. Europe Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. Europe Rare Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. Europe Rare Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. Europe Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. Europe Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 208. Europe Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 209. Europe Rare Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 210. Europe Rare Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Germany Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 212. France Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 213. U.K. Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 214. Italy Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 215. Netherlands Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 216. China Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 217. China Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 218. China Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 219. China Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 220. China Rare Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 221. China Rare Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 222. China Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 223. China Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 224. China Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 225. China Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 226. China Rare Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 227. China Rare Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 228. Asia Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 229. Asia Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 230. Asia Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 231. Asia Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 232. Asia Rare Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 233. Asia Rare Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 234. Asia Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 235. Asia Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 236. Asia Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 237. Asia Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 238. Asia Rare Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 239. Asia Rare Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 240. Asia Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 241. Asia Rare Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 242. Asia Rare Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 243. Asia Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 244. Asia Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 245. Asia Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 246. Asia Rare Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 247. Asia Rare Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 248. Japan Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 249. South Korea Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 250. India Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 251. Australia Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 252. China Taiwan Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 253. Southeast Asia Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 254. SAMEA Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 255. SAMEA Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 256. SAMEA Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 257. SAMEA Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 258. SAMEA Rare Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 259. SAMEA Rare Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 260. SAMEA Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 261. SAMEA Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 262. SAMEA Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 263. SAMEA Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 264. SAMEA Rare Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 265. SAMEA Rare Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 266. SAMEA Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 267. SAMEA Rare Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 268. SAMEA Rare Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 269. SAMEA Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 270. SAMEA Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 271. SAMEA Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 272. SAMEA Rare Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 273. SAMEA Rare Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 274. Brazil Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 275. Argentina Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 276. Chile Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 277. Colombia Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 278. Peru Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 279. Saudi Arabia Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 280. Israel Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 281. UAE Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 282. Turkey Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 283. Iran Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 284. Egypt Rare Disease Drug Revenue (2021-2032) & (US$ Million) Table 285. Key Raw Materials Table 286. Raw Materials Key Suppliers Table 287. Rare Disease Drug Distributors List Table 288. Rare Disease Drug Customers List Table 289. Research Programs/Design for This Report Table 290. Authors List of This Report Table 291. Secondary Sources Table 292. Primary Sources List of Figures Figure 1. Rare Disease Drug Image Figure 2. Global Rare Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Below 0.1‰ Image Figure 5. Above 1‰ Image Figure 6. 0.65‰～1‰ Image Figure 7. Global Rare Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Rare Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Speciality Pharmacies Image Figure 10. Hospital Pharmacies Image Figure 11. Retail pharmacies Image Figure 12. Others Image Figure 13. Global Rare Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Rare Disease Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Rare Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Rare Disease Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Rare Disease Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Rare Disease Drug Sales (2021-2032) & (K Units) Figure 19. Global Rare Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Rare Disease Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Rare Disease Drug Sales YoY (2021-2032) & (K Units) Figure 22. Europe Rare Disease Drug Sales YoY (2021-2032) & (K Units) Figure 23. China Rare Disease Drug Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Rare Disease Drug Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Rare Disease Drug Sales YoY (2021-2032) & (K Units) Figure 26. Global Rare Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Rare Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Rare Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Rare Disease Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Rare Disease Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Rare Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Rare Disease Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Rare Disease Drug Sales Market Share by Type (2021-2032) Figure 35. Global Rare Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Rare Disease Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Rare Disease Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Rare Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Rare Disease Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Rare Disease Drug Sales Market Share by Application (2021-2032) Figure 41. North America Rare Disease Drug Revenue Share by Type (2021-2032) Figure 42. North America Rare Disease Drug Sales Share by Type (2021-2032) Figure 43. North America Rare Disease Drug Revenue Share by Application (2021-2032) Figure 44. North America Rare Disease Drug Sales Share by Application (2021-2032) Figure 45. North America Rare Disease Drug Revenue Share by Country (2021-2032) Figure 46. North America Rare Disease Drug Sales Share by Country (2021-2032) Figure 47. Europe Rare Disease Drug Revenue Share by Type (2021-2032) Figure 48. Europe Rare Disease Drug Sales Share by Type (2021-2032) Figure 49. Europe Rare Disease Drug Revenue Share by Application (2021-2032) Figure 50. Europe Rare Disease Drug Sales Share by Application (2021-2032) Figure 51. Europe Rare Disease Drug Revenue Share by Country (2021-2032) Figure 52. Europe Rare Disease Drug Sales Share by Country (2021-2032) Figure 53. China Rare Disease Drug Revenue Share by Type (2021-2032) Figure 54. China Rare Disease Drug Sales Share by Type (2021-2032) Figure 55. China Rare Disease Drug Revenue Share by Application (2021-2032) Figure 56. China Rare Disease Drug Sales Share by Application (2021-2032) Figure 57. Asia Rare Disease Drug Revenue Share by Type (2021-2032) Figure 58. Asia Rare Disease Drug Sales Share by Type (2021-2032) Figure 59. Asia Rare Disease Drug Revenue Share by Application (2021-2032) Figure 60. Asia Rare Disease Drug Sales Share by Application (2021-2032) Figure 61. Asia Rare Disease Drug Revenue Share by Country (2021-2032) Figure 62. Asia Rare Disease Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Rare Disease Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Rare Disease Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Rare Disease Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Rare Disease Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Rare Disease Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Rare Disease Drug Sales Share by Country (2021-2032) Figure 69. Rare Disease Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Rare Disease Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Below 0.1‰
  • Above 1‰
  • 0.65‰～1‰
Applications
  • Speciality Pharmacies
  • Hospital Pharmacies
  • Retail pharmacies
  • Others
Companies covered
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • Atara Biotherapeutics
  • Bayer AG
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • Deciphera
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • ProQR
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rare Disease Drug Market by Type
  3. 1.2.1 Global Rare Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Below 0.1‰
  5. 1.2.3 Above 1‰
  6. 1.2.4 0.65‰～1‰
  7. 1.3 Rare Disease Drug Market by Application
  8. 1.3.1 Global Rare Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Speciality Pharmacies
  10. 1.3.3 Hospital Pharmacies
  11. 1.3.4 Retail pharmacies
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Rare Disease Drug Market Dynamics
  1. 2.1 Rare Disease Drug Industry Trends
  2. 2.2 Rare Disease Drug Industry Drivers
  3. 2.3 Rare Disease Drug Industry Opportunities and Challenges
  4. 2.4 Rare Disease Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Rare Disease Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Rare Disease Drug Revenue by Region
  3. 3.2.1 Global Rare Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rare Disease Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Rare Disease Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Rare Disease Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Rare Disease Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Rare Disease Drug Sales by Region
  9. 3.4.1 Global Rare Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Rare Disease Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Rare Disease Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Rare Disease Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Rare Disease Drug Revenue by Manufacturers
  2. 4.1.1 Global Rare Disease Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Rare Disease Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Rare Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rare Disease Drug Sales by Manufacturers
  6. 4.2.1 Global Rare Disease Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Rare Disease Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Rare Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Rare Disease Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Rare Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Rare Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Rare Disease Drug Manufacturers, Product Type & Application
  13. 4.7 Global Rare Disease Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Rare Disease Drug Market CR5 and HHI
  16. 4.8.2 2025 Rare Disease Drug Tier 1, Tier 2, and Tier 3
5 Rare Disease Drug Market by Type
  1. 5.1 Global Rare Disease Drug Revenue by Type
  2. 5.1.1 Global Rare Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Rare Disease Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Rare Disease Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Rare Disease Drug Sales by Type
  6. 5.2.1 Global Rare Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Rare Disease Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Rare Disease Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Rare Disease Drug Price by Type
6 Rare Disease Drug Market by Application
  1. 6.1 Global Rare Disease Drug Revenue by Application
  2. 6.1.1 Global Rare Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Rare Disease Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Rare Disease Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Rare Disease Drug Sales by Application
  6. 6.2.1 Global Rare Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Rare Disease Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Rare Disease Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Rare Disease Drug Price by Application
7 Company Profiles
  1. 7.1 Alexion Pharmaceuticals, Inc.
  2. 7.1.1 Alexion Pharmaceuticals, Inc. Company Information
  3. 7.1.2 Alexion Pharmaceuticals, Inc. Business Overview
  4. 7.1.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio
  6. 7.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
  7. 7.2 Amgen, Inc.
  8. 7.2.1 Amgen, Inc. Company Information
  9. 7.2.2 Amgen, Inc. Business Overview
  10. 7.2.3 Amgen, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen, Inc. Rare Disease Drug Product Portfolio
  12. 7.2.5 Amgen, Inc. Recent Developments
  13. 7.3 Atara Biotherapeutics
  14. 7.3.1 Atara Biotherapeutics Company Information
  15. 7.3.2 Atara Biotherapeutics Business Overview
  16. 7.3.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Atara Biotherapeutics Rare Disease Drug Product Portfolio
  18. 7.3.5 Atara Biotherapeutics Recent Developments
  19. 7.4 Bayer AG
  20. 7.4.1 Bayer AG Company Information
  21. 7.4.2 Bayer AG Business Overview
  22. 7.4.3 Bayer AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bayer AG Rare Disease Drug Product Portfolio
  24. 7.4.5 Bayer AG Recent Developments
  25. 7.5 Biogen, Inc.
  26. 7.5.1 Biogen, Inc. Company Information
  27. 7.5.2 Biogen, Inc. Business Overview
  28. 7.5.3 Biogen, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Biogen, Inc. Rare Disease Drug Product Portfolio
  30. 7.5.5 Biogen, Inc. Recent Developments
  31. 7.6 Bristol-Myers Squibb Company
  32. 7.6.1 Bristol-Myers Squibb Company Company Information
  33. 7.6.2 Bristol-Myers Squibb Company Business Overview
  34. 7.6.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 7.7 Celgene Corporation
  38. 7.7.1 Celgene Corporation Company Information
  39. 7.7.2 Celgene Corporation Business Overview
  40. 7.7.3 Celgene Corporation Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Celgene Corporation Rare Disease Drug Product Portfolio
  42. 7.7.5 Celgene Corporation Recent Developments
  43. 7.8 Daiichi Sankyo Company Limited
  44. 7.8.1 Daiichi Sankyo Company Limited Company Information
  45. 7.8.2 Daiichi Sankyo Company Limited Business Overview
  46. 7.8.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio
  48. 7.8.5 Daiichi Sankyo Company Limited Recent Developments
  49. 7.9 Deciphera
  50. 7.9.1 Deciphera Company Information
  51. 7.9.2 Deciphera Business Overview
  52. 7.9.3 Deciphera Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Deciphera Rare Disease Drug Product Portfolio
  54. 7.9.5 Deciphera Recent Developments
  55. 7.10 Eisai Co., Ltd.
  56. 7.10.1 Eisai Co., Ltd. Company Information
  57. 7.10.2 Eisai Co., Ltd. Business Overview
  58. 7.10.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Eisai Co., Ltd. Rare Disease Drug Product Portfolio
  60. 7.10.5 Eisai Co., Ltd. Recent Developments
  61. 7.11 F. Hoffmann-La Roche Ltd.
  62. 7.11.1 F. Hoffmann-La Roche Ltd. Company Information
  63. 7.11.2 F. Hoffmann-La Roche Ltd. Business Overview
  64. 7.11.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio
  66. 7.11.5 F. Hoffmann-La Roche Ltd. Recent Developments
  67. 7.12 Novo Nordisk A/S
  68. 7.12.1 Novo Nordisk A/S Company Information
  69. 7.12.2 Novo Nordisk A/S Business Overview
  70. 7.12.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Novo Nordisk A/S Rare Disease Drug Product Portfolio
  72. 7.12.5 Novo Nordisk A/S Recent Developments
  73. 7.13 ProQR
  74. 7.13.1 ProQR Company Information
  75. 7.13.2 ProQR Business Overview
  76. 7.13.3 ProQR Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 ProQR Rare Disease Drug Product Portfolio
  78. 7.13.5 ProQR Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Rare Disease Drug Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 GlaxoSmithKline
  86. 7.15.1 GlaxoSmithKline Company Information
  87. 7.15.2 GlaxoSmithKline Business Overview
  88. 7.15.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 GlaxoSmithKline Rare Disease Drug Product Portfolio
  90. 7.15.5 GlaxoSmithKline Recent Developments
  91. 7.16 Pfizer, Inc.
  92. 7.16.1 Pfizer, Inc. Company Information
  93. 7.16.2 Pfizer, Inc. Business Overview
  94. 7.16.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Pfizer, Inc. Rare Disease Drug Product Portfolio
  96. 7.16.5 Pfizer, Inc. Recent Developments
  97. 7.17 Eli Lilly and Company
  98. 7.17.1 Eli Lilly and Company Company Information
  99. 7.17.2 Eli Lilly and Company Business Overview
  100. 7.17.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Eli Lilly and Company Rare Disease Drug Product Portfolio
  102. 7.17.5 Eli Lilly and Company Recent Developments
  103. 7.18 Merck & Co., Inc.
  104. 7.18.1 Merck & Co., Inc. Company Information
  105. 7.18.2 Merck & Co., Inc. Business Overview
  106. 7.18.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Merck & Co., Inc. Rare Disease Drug Product Portfolio
  108. 7.18.5 Merck & Co., Inc. Recent Developments
  109. 7.19 Novartis AG
  110. 7.19.1 Novartis AG Company Information
  111. 7.19.2 Novartis AG Business Overview
  112. 7.19.3 Novartis AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Novartis AG Rare Disease Drug Product Portfolio
  114. 7.19.5 Novartis AG Recent Developments
  115. 7.20 Johnson & Johnson
  116. 7.20.1 Johnson & Johnson Company Information
  117. 7.20.2 Johnson & Johnson Business Overview
  118. 7.20.3 Johnson & Johnson Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Johnson & Johnson Rare Disease Drug Product Portfolio
  120. 7.20.5 Johnson & Johnson Recent Developments
  121. 7.21 Sanofi S.A.
  122. 7.21.1 Sanofi S.A. Company Information
  123. 7.21.2 Sanofi S.A. Business Overview
  124. 7.21.3 Sanofi S.A. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Sanofi S.A. Rare Disease Drug Product Portfolio
  126. 7.21.5 Sanofi S.A. Recent Developments
  127. 7.22 Takeda
  128. 7.22.1 Takeda Company Information
  129. 7.22.2 Takeda Business Overview
  130. 7.22.3 Takeda Rare Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Takeda Rare Disease Drug Product Portfolio
  132. 7.22.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Rare Disease Drug Market Size by Type
  2. 8.1.1 North America Rare Disease Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Rare Disease Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Rare Disease Drug Price by Type (2021-2032)
  5. 8.2 North America Rare Disease Drug Market Size by Application
  6. 8.2.1 North America Rare Disease Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Rare Disease Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Rare Disease Drug Price by Application (2021-2032)
  9. 8.3 North America Rare Disease Drug Market Size by Country
  10. 8.3.1 North America Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Rare Disease Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Rare Disease Drug Market Size by Type
  2. 9.1.1 Europe Rare Disease Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Rare Disease Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Rare Disease Drug Price by Type (2021-2032)
  5. 9.2 Europe Rare Disease Drug Market Size by Application
  6. 9.2.1 Europe Rare Disease Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Rare Disease Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Rare Disease Drug Price by Application (2021-2032)
  9. 9.3 Europe Rare Disease Drug Market Size by Country
  10. 9.3.1 Europe Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Rare Disease Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Rare Disease Drug Market Size by Type
  2. 10.1.1 China Rare Disease Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Rare Disease Drug Sales by Type (2021-2032)
  4. 10.1.3 China Rare Disease Drug Price by Type (2021-2032)
  5. 10.2 China Rare Disease Drug Market Size by Application
  6. 10.2.1 China Rare Disease Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Rare Disease Drug Sales by Application (2021-2032)
  8. 10.2.3 China Rare Disease Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rare Disease Drug Market Size by Type
  2. 11.1.1 Asia Rare Disease Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Rare Disease Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Rare Disease Drug Price by Type (2021-2032)
  5. 11.2 Asia Rare Disease Drug Market Size by Application
  6. 11.2.1 Asia Rare Disease Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Rare Disease Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Rare Disease Drug Price by Application (2021-2032)
  9. 11.3 Asia Rare Disease Drug Market Size by Country
  10. 11.3.1 Asia Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Rare Disease Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rare Disease Drug Market Size by Type
  2. 12.1.1 SAMEA Rare Disease Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Rare Disease Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Rare Disease Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Rare Disease Drug Market Size by Application
  6. 12.2.1 SAMEA Rare Disease Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Rare Disease Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Rare Disease Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Rare Disease Drug Market Size by Country
  10. 12.3.1 SAMEA Rare Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Rare Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Rare Disease Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Rare Disease Drug Value Chain Analysis
  2. 13.1.1 Rare Disease Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Rare Disease Drug Production Mode & Process
  6. 13.2 Rare Disease Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Rare Disease Drug Distributors
  9. 13.2.3 Rare Disease Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst